Q Biomed Technology Partner Mannin Research Inc. To Participate In A Webcast On Innovating For Ophthalmic Diseases

Biotech Investing
Biotech Investing

NEW YORK, October 19, 2016 — Q BioMed Inc. (OTCQB:QBIO), technology partner Mannin Research Inc. will present in a webcast on Innovating for Ophthalmic Diseases on October 20th at 10AM ET.

NEW YORK, October 19, 2016 — Q BioMed Inc. (OTCQB:QBIO), technology partner Mannin Research Inc. will present in a webcast on Innovating for Ophthalmic Diseases on October 20th at 10AM ET.
Dr. George Nikopoulos, CEO and President of Mannin Research Inc. will participate in a BioPharma Dealmakers webcast, sponsored in part by Mannin Research Inc., featuring three companies innovating in therapies for eye disorders.
Please register here to participate > Webcast registration link
This webcast will explore some of the latest advances in the ophthalmic field through discussion with representatives from companies developing a range of innovative therapies for eye disorders, including the use of iPS cells, eye drops to deliver small-molecule drugs and complement inhibition.
The webcast will conclude with a live roundtable discussion and a Q&A section to allow you to participate and put your own questions to the speakers.
Dr. Nikopoulos has worked with and advised a number of biotechnology, pharmaceutical and med-tech companies. Dr. Nikopoulos’ expertise includes translating complex technologies and innovations into strategies for commercialization, market research, and business development as well as pre-clinical toxicology study design.
Other webcast participants include:

  • Hardy TS Kagimoto, MD, President, Representative Director and CEO of HEALIOS K.K.
  • Dr. George Nikopoulos, CEO & President of Mannin Research Inc.
  • Moderator: Raveena Bhambra, Editor of BioPharma Dealmakers. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing.

Connect with Q BioMed Inc. (OTCQB:QBIO) to receive an Investor Presentation.

The Conversation (0)
×